市場調查報告書

治療及預防疫苗的全球市場預測(2019年∼2025年)

Global Therapeutic and Preventive Vaccine Market 2019-2025

出版商 Orion Market Research Pvt Ltd 商品編碼 920444
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
Back to Top
治療及預防疫苗的全球市場預測(2019年∼2025年) Global Therapeutic and Preventive Vaccine Market 2019-2025
出版日期: 2019年12月18日內容資訊: 英文
簡介

全球治療及預防疫苗市場,預計在預測期間內以9.3%的驚人成長率發展。促進市場成長的主要原因,是全世界的癌症和其他感染疾病等的慢性疾病的盛行率上升。政府支出,由於癌症的治療而顯著增加。美國,對2010年的癌症治療的國家支出近1,250億美元,預計2020年達到1,560億美元。乳癌是女性的死亡率的主要原因之一。美國,2017年有252,000名以上的乳癌新病例。這些數字,反映疫苗接種的必要性,因此促進市場成長。再加上DNA疫苗等創新的疫苗開發的關注高漲,中國和印度等新興經濟國的疫苗接種的優點認識的高漲,更加強化著市場成長。

本報告提供全球治療及預防疫苗市場相關調查分析,市場概要,市場決策要素,市場區隔,競爭情形,各地區分析,主要企業等相關的系統性資訊。

目錄

第1章 報告概要

  • 調查方法與工具
  • 市場分析
    • 各市場區隔
    • 各地區

第2章 市場概要與考察

  • 報告的範圍
  • 分析師的考察和最新市場趨勢
    • 主要調查結果
    • 建議
    • 結論
  • 規則、規定

第3章 競爭環境

  • 企業佔有率分析
  • 主要策略分析
  • 主要企業分析
    • Sanofi SA
    • Pfizer Inc.
    • GlaxoSmithKline PLC
    • Merck & Co.
    • AstraZeneca PLC

第4章 市場決策要素

  • 成長促進因素
  • 阻礙因素
  • 市場機會

第5章 市場區隔

  • 各類型市場
    • 治療疫苗
    • 預防疫苗
  • 疾病類型市場
    • 自體免疫疾病
    • 神經疾病
    • 癌症
    • 感染疾病
  • 各疫苗類型治療疫苗市場
    • 同類疫苗
    • 自我疫苗
  • 各疾病類型預防疫苗市場
    • 肺炎球菌
    • 脊髓灰質炎病毒
    • 肝炎
    • 流感
    • 麻疹,腮腺炎,德國麻疹
    • 其他(水痘)
  • 疫苗各類型預防疫苗市場
    • 活病毒疫苗/弱毒疫苗
    • 不活化疫苗
    • 共軛疫苗
    • DNA疫苗
    • 其他(重組載體疫苗)
  • 各終端用戶市場
    • 動物

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他
  • 其他地區

第7章 公司概要

  • Agenus Inc.
  • Argos Therapeutic Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Celldex Therapeutic Inc.
  • CSL Ltd.
  • Cytos Biotechnology AG
  • 第一三共
  • Dendreon Corp
  • Emergent BioSolutions Inc.
  • GC Pharma (Green Cross Corp.)
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co.
  • Novartis International AG
  • Novavax Inc.
  • Pfizer Inc.
  • Qed Biosciences Inc.
  • Sanofi SA
  • 武田藥品工業
  • Vaccinogen Inc.
  • Xenetic Biosciences, Inc.
  • Zoetis Inc.
目錄
Product Code: OMR2020042

The global therapeutic and preventive vaccine market is estimated to grow at an impressive growth rate of 9.3% during the forecast period. Major factors that augment the market growth include the rising prevalence of chronic diseases such as cancer and other infectious diseases across the globe. The expenditure of the government is increasing significantly for the cure for cancer. In the US, national expenditures for cancer care were near to $125 billion in 2010 and it is expected to reach $156 billion in 2020. Breast cancer is one of the leading causes of mortality among women. In the US, there were more than 252,000 new cases of breast cancer in 2017. These figures reflect the need for vaccination; thereby, augmenting the market growth. Moreover, growing focus on the development of innovative vaccines such as DNA vaccines and growing awareness towards the benefits of vaccination in emerging economies such as China and India is further augmenting the market growth.

The global therapeutic and preventive vaccine market is segmented on the basis of type, end-user, and region. On the basis of type, the market is broadly classified into the therapeutic vaccine and preventive vaccine. The global therapeutic vaccine market is analyzed on the basis of disease type and vaccine type. On the basis of disease, the therapeutic vaccine market is sub-segmented into autoimmune disease vaccine, neurological disease vaccine, and cancer vaccine. On the basis of vaccine type, the market is analyzed into an allogeneic vaccine and autologous vaccine. Whereas, the global preventive vaccine market is further segmented on the basis of vaccine type and disease type. On the basis of vaccine type, the market is classified into live/attenuated vaccine, inactivated vaccine, conjugate vaccine, DNA vaccines, and others. Based on disease type, the market analyzes pneumococcal, poliovirus, hepatitis, influenza, measles, mumps, and rubella and others. Based on the end-user, the global therapeutic and preventive vaccine market is divided into human vaccines and animal vaccines.

Geographically, the market is analyzed into North America, Europe, Asia-Pacific, and the Rest of the World. North America held the dominating position in the global therapeutic and preventive vaccine market in 2018 and is further estimated to follow the same trend over the forecast period. The major factors contributing to the growth of the North American market include the presence of well-developed healthcare infrastructure, the number of researches carried out on vaccination and fund provided to the companies and institutions, unhealthy lifestyle and growing focus on the treatment of cancer. Further, Asia-Pacific is estimated to be the fastest-growing region during the forecast period. Moreover, the global therapeutic and preventive vaccine market is influenced by the presence of several players including Sanofi SA, Pfizer Inc., GlaxoSmithKline PLC, Merck & Co., AstraZeneca PLC, and many others. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Research Methodology

The market study of the global therapeutic and preventive vaccine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market
  • Authenticate databases such as the World Health Organizations (WHO), the National Institute of Health (NIH), and others.
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for therapeutic and preventive vaccine manufacturers, research organizations, pharmaceutical drug manufacturing companies, biotechnology companies, venture capitalists, market research firms, government organizations and regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Therapeutic and Preventive Vaccine Market Research and Analysis by Type

2. Global Therapeutic and Preventive Vaccine Market Research and Analysis by End-User

The Report covers:

  • Comprehensive research methodology of the global therapeutic and preventive vaccine market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global therapeutic and preventive vaccine market.
  • Insights about market determinants which are stimulating the global therapeutic and preventive vaccine market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Sanofi SA
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Pfizer Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. GlaxoSmithKline PLC
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Merck & Co.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. AstraZeneca PLC
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Therapeutic and Preventive Vaccine Market by Type
    • 5.1.1. Therapeutic Vaccine
    • 5.1.2. Preventive Vaccine
  • 5.2. Global Therapeutic Vaccine Market by Disease Type
    • 5.2.1. Autoimmune Disease
    • 5.2.2. Neurological Disease
    • 5.2.3. Cancer
    • 5.2.4. Infectious Disease
  • 5.3. Global Therapeutic Vaccine Market by Vaccine Type
    • 5.3.1. Allogeneic Vaccine
    • 5.3.2. Autologous Vaccine
  • 5.4. Global Preventive Vaccine Market by Disease Type
    • 5.4.1. Pneumococcal
    • 5.4.2. Poliovirus
    • 5.4.3. Hepatitis
    • 5.4.4. Influenza
    • 5.4.5. Measles, Mumps, and Rubella
    • 5.4.6. Others (Varicella)
  • 5.5. Global Preventive Vaccine Market by Vaccine Type
    • 5.5.1. Live/Attenuated Vaccine
    • 5.5.2. Inactivated Vaccine
    • 5.5.3. Conjugate Vaccine
    • 5.5.4. DNA Vaccines
    • 5.5.5. Others (Recombinant Vector Vaccines)
  • 5.6. Global Therapeutic and Preventive Vaccine Market by End-User
    • 5.6.1. Human
    • 5.6.2. Animal

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. Japan
    • 6.3.3. India
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Agenus Inc.
  • 7.2. Argos Therapeutic Inc.
  • 7.3. Astellas Pharma Inc.
  • 7.4. AstraZeneca PLC
  • 7.5. Celldex Therapeutic Inc.
  • 7.6. CSL Ltd.
  • 7.7. Cytos Biotechnology AG
  • 7.8. Daiichi Sankyo Co. Ltd
  • 7.9. Dendreon Corp
  • 7.10. Emergent BioSolutions Inc.
  • 7.11. GC Pharma (Green Cross Corp.)
  • 7.12. GlaxoSmithKline PLC
  • 7.13. Johnson & Johnson Services Inc.
  • 7.14. Merck & Co.
  • 7.15. Novartis International AG
  • 7.16. Novavax Inc.
  • 7.17. Pfizer Inc.
  • 7.18. Qed Biosciences Inc.
  • 7.19. Sanofi SA
  • 7.20. Takeda Pharmaceutical Co. Ltd.
  • 7.21. Vaccinogen Inc.
  • 7.22. Xenetic Biosciences, Inc.
  • 7.23. Zoetis Inc.

List of Tables

  • 1. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 2. GLOBAL THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL NEUROLOGICAL DISEASE THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL CANCER THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 8. GLOBAL INFECTIOUS DISEASE THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2018-2025 ($ MILLION)
  • 10. GLOBAL ALLOGENEIC THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 11. GLOBAL AUTOLOGOUS THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 12. GLOBAL PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 13. GLOBAL PREVENTIVE VACCINE FOR PNEUMOCOCCAL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 14. GLOBAL PREVENTIVE VACCINE FOR POLIOVIRUS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 15. GLOBAL PREVENTIVE VACCINE FOR HEPATITIS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 16. GLOBAL PREVENTIVE VACCINE FOR INFLUENZA DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 17. GLOBAL PREVENTIVE VACCINE FOR MMR DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 18. GLOBAL PREVENTIVE VACCINE FOR OTHER DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 19. GLOBAL PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2018-2025 ($ MILLION)
  • 20. GLOBAL LIVE/ATTENUATED PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 21. GLOBAL INACTIVATED PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 22. GLOBAL CONJUGATE PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 23. GLOBAL DNA PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 24. GLOBAL OTHER PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 25. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 26. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE FOR HUMAN MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 27. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE FOR ANIMAL MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 28. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 29. NORTH AMERICAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 30. NORTH AMERICAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 31. NORTH AMERICAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 32. EUROPEAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 33. EUROPEAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 34. EUROPEAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 35. ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 36. ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 37. ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 38. REST OF THE WORLD THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 39. REST OF THE WORLD THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

List of Figures

  • 1. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET SHARE BY TYPE, 2018 VS 2025 (%)
  • 2. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET SHARE BY END-USER, 2018 VS 2025 (%)
  • 3. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 4. US THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. CANADA THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. UK THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. GERMANY THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. ITALY THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. SPAIN THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. ROE THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. INDIA THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF THE WORLD THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
Back to Top